A carregar...
Risky business: target choice in adoptive cell therapy
In this issue of Blood, Casucci et al present an elegant study that describes a potential new target for adoptive cell transfer (ACT), in this case CD44 splice variant 6 (CD44v6), and detail why it may be a good target for ACT and how to manage expected off-tumor/on-target toxicities.(1)
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3829111/ https://ncbi.nlm.nih.gov/pubmed/24235126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-09-527622 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|